… Targeting such minimal residual disease may lead to improved … Our manuscript describes
the clinical impact of a K562/GM-CSF … -colony stimulating factor (GM-CSF) is a vaccine derived …

… We analyzed the minimal residual disease by RT-PCR BCR/ABL in some surviving mice (…
-transduced cells and one mice from the GM-CSF vaccine group were positive by BCR/ABL RT-…

… dose of GMCSF-producing B9 cells. Local treatment of TC-1 SMRTD with rGM-CSF resulted
in a significant inhibition of tumour growth (P<0.05) and significant reduction of the tumour …

… to produce GM-CSF. A pilot vaccination strategy was developed to determine if K562/GM-CSF …
responses in pts having persistent, measurable disease despite 1 or more years on IM. …

… Notably, 6 of 7 responders but only 1 of 8 patients with disease progression developed
leukocytosis during therapy. Therefore, we conclude that continuous low-dose GM-CSF has …

… Minimal residual disease in cancer can be detected by identification of epithelial tumor cells
in bone marrow using monoclonal antibodies directed against cytokeratin. The presence of …

… However, its benefit has been limited to patients with minimal residual disease, and dose-escalation
has been limited by significant systemic toxicities. The optimal use of cytokines may …

… Adjuvant radiotherapy was allowed in patients in whom residual disease was suspected
postoperatively. Patients were not excluded if they had received prior chemotherapy, radiation …

… Indeed, as soon as recombinant GMCSF or G-CSF were available for medical practice, …
index'2-39 and the binding of GM-CSF or G-CSF to AML cells was studied and the receptors of …

… residual disease. Cellular CD116 expression was documented in &gt; 50% M0 AML. Since
the activity of GM-CSF … hypothesised that the clinical use of GM-CSF in AML patients could be …